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ABSTRACT
Introduction: Major depressive disorder (MDD) is a
leading cause of disease and disability globally and in
South Africa. Epidemiological data for MDD are
essential to estimate the overall disease burden in a
country. The objective of the systematic review is to
examine the evidence base for prevalence, incidence,
remission, duration, severity, case fatality and excess
mortality of MDD in South Africa from 1997 to 2015.
Methods and analysis: We will perform electronic
searches in PubMed, PsycINFO, Scopus and other
bibliographical databases. Articles published between
January 1997 and December 2015 will be eligible for
inclusion in this review. The primary outcomes will be
prevalence, incidence, remission, duration, severity, case
fatality and excess mortality of MDD. The secondary
outcomes will be risk factors and selected populations
for MDD. If appropriate, a meta-analysis will be
performed. If a meta-analysis is not possible, the review
findings will be presented narratively and in tables.
Subgroup analyses will be conducted with subgroups
defined by population group, rural/urban settings and
study designs, if sufficient data are available.
Ethics and dissemination: The systematic review will
use published data that are not linked to individuals. The
review findings may have implications for future research
prioritisation and disease modelling of MDD to estimate
its morbidity burden in South Africa, and will be
disseminated electronically and in print through peer-
reviewed publications.
Trial Registration number: International Prospective
Register of Systematic Reviews (PROSPERO)
CRD42015024885.
INTRODUCTION
Major depressive disorder (MDD), a
common mental disorder, is among the
leading three causes of disease burden glo-
bally and in South Africa. Globally, the preva-
lence of MDD is estimated to have increased
signiﬁcantly by 53% from 1990 to reach over
253 million prevalent cases in 2013. On a
similar scale, the years lived with disability
(YLDs) for MDD globally increased
signiﬁcantly by 53% from 1990 to reach 52
million YLDs in 2013.1 In South Africa, too,
the YLDs for MDD increased signiﬁcantly by
58% from 1990 to reach 408578 YLDs in
2013.2 Much of the increases arose from the
growth and ageing of the population as well
as the widespread under-resourcing of
mental health services in South Africa, result-
ing in underdiagnoses and undertreatment
of mental disorders (including MDD).3
The ﬁrst port of entry for South Africans is
often the primary healthcare setting.4
However, the literature shows that there are
barriers to help-seeking and treatment-
seeking for mental illnesses.5–7 Reasons in
the literature include stigma, low health liter-
acy levels (in terms of knowledge of the
disease and its treatment) and ﬁnancial
Strengths and limitations of this study
▪ To the best of our knowledge, this is the first
systematic review to assess the evidence base
on the epidemiological parameters and risk
factors for major depressive disorder (MDD) in
South Africa.
▪ The study is likely to provide epidemiological
parameters commonly used in modelling health
conditions with the purpose of estimating the
morbidity burden in a country, and to subse-
quently help guide resource prioritisation,
decision-making and policy development.
▪ This protocol complies with the ‘Preferred
Reporting Items for Systematic Review and
Meta-Analysis Protocols (PRISMA-P) 2015’
guidelines.
▪ There are several assessment tools to measure
MDD which may limit comparison across
studies.
▪ Observational studies with a high risk of bias
may present a limitation to the study. We will,
however, investigate the robustness of the
methods and results by using a risk of bias tool
and excluding studies with a high risk of bias.
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difﬁculties.6 In addition, comorbidity complicates help-
seeking and treatment-seeking for mental illness.5 7
Moreover, mental disorders (including MDD) often go
unrecognised by healthcare providers and therefore
untreated in primary health settings.8 They are disabling
and associated with a signiﬁcant economic burden at
both the individual and societal levels, resulting from a
reduction in health-related quality of life, disrupted
work and life roles, as well as increased morbidity and
mortality.4 9–11
Health in South Africa is characterised by an enor-
mous and diverse burden of disease12–15 and comorbid-
ity of MDD with a range of other conditions is a reason
for concern. MDD, for example, is comorbid with infec-
tious diseases, such as HIV/AIDS,7 which are pandemic
in the country. MDD is also associated with non-
communicable diseases,16 high rates of violence and
injury17 and maternal and child illness.18 In addition,
South Africans may be at risk for neuropsychiatric disor-
ders given the high levels of unemployment and
poverty,19 high rates of crime, inadequate social services
and other potentially stressful living conditions such as
poor and unstable housing.20 Moreover, evidence sug-
gests that MDD is comorbid with a variety of psychiatric
conditions and medical conditions as well as substance
use disorders.4 21 It is therefore reasonable to argue
that, with the high burden of disease,13 22 23 and
shortages in healthcare resources and the potentially
adverse living conditions in South Africa,12 24–26 MDD is
likely to be highly prevalent.
MDD in the Diagnostic and Statistical Manual of
Mental Disorders, Fifth Edition (DSM-V)27 is charac-
terised by one or more major depressive episodes,
lasting for at least 2 weeks. This closely resembles the cri-
teria for recurrent depressive disorder in the existing
International Statistical Classiﬁcation of Diseases and
Related Health Problems, 10th Revision (ICD-10).28 An
MDD episode involves symptoms of depressed mood
and/or loss of interest or pleasure in all or most activ-
ities, occurring most of the day and nearly every day,
plus at least ﬁve of the following symptoms: appetite or
weight change, sleep disturbances, restlessness, fatigue,
feelings of guilt or worthlessness, impaired concentra-
tion and suicidal ideation.29 The DSM-V criteria for
MDD have remained mostly unchanged from the fourth
edition of the text revision of the DSM, (DSM-IV-TR).
DSM-V has eliminated the bereavement exclusion and
acknowledged the mixed features of MDD.30 In add-
ition, the proposed 11th revision of the ICD criteria for
recurrent depressive disorder may differ from those in
ICD-10. The suggestion has been made to use only one
overall depressive episode diagnosis, with the distinction
between ﬁrst and recurrent episode to become a
subtype or be abandoned.31
Diagnosis of MDD as per the criteria outlined in the
DSM-V and DSM-IV-TR involves establishing the severity
of symptoms and their duration as well as the degree of
impairment.4 32 There are a variety of assessment
instruments that may be useful in providing an indica-
tion of the severity of symptoms and assessing the sever-
ity of symptoms over a speciﬁed time period.4 32 These
range from self-administered assessment instruments to
interviewer-administered assessment instruments.32
Furthermore, diagnosis is guided by both a patient
history and examination to rule out any underlying
comorbid psychiatric disorder, substance use disorder
and general medical conditions.4 32 Finally, the literature
indicates that diagnostic criteria are useful to follow for
the diagnosis of MDD but must be applied with clinical
judgement, because the symptoms of depression may
vary across gender, age and cultural group.32
The second South African National Burden of Disease
Study, which estimates the disease burden for the country
using different summary measures of population health,
including the disability-adjusted life year (DALY), is cur-
rently underway. The DALY combines the health loss
from premature mortality (or years of life lost (YLLs))
and the loss of healthy life from disability associated with
non-fatal outcomes (or YLDs). An essential prerequisite
for estimating the DALY is the availability of nationally
representative epidemiological data. We therefore aim to
assess the evidence base for prevalence, incidence, remis-
sion, duration, severity, case fatality and excess mortality
of MDD in South Africa from 1997 to 2015. A secondary
aim is to identify risk factors for MDD.
METHODS
Criteria for included studies
Types of studies
We will include population-based surveys, prospective or
retrospective cohort, case–control and cross-sectional
studies published in English, with more than 100 partici-
pants, that reported on the epidemiological parameters
of interest in the general population and in speciﬁc
populations such as those with chronic diseases (includ-
ing HIV), pregnancy and those exposed to trauma or
negative life experiences. Studies that report on cases
which met diagnostic criteria for MDD as described in
the DSM-V/DSM-IV-TR or ICD-10 will be included.
Studies in which a measurement tool was used to screen
for and diagnose MDD will also be included.
For prevalence, we will include studies reporting point
(ie, current or past month prevalence) and period
prevalence (ie, 6-month and/or 12-month prevalence).
For incidence, we will include studies reporting on
cumulative incidence rates (ie, number of new cases in a
speciﬁed time period in a population at risk) or inci-
dence rates (ie, number of new cases over total person-
years of follow-up susceptible).33 For remission, we will
include studies reporting on a rescinded diagnosis of
MDD (ie, DSM-V/DSM-IV-TR or ICD-10 criteria no
longer met). For duration, we will include studies report-
ing on time to end of a major depressive episode.34 For
severity, we will include studies reporting on severity (ie,
mild, moderate or severe) based on DSM-V/DSM-IV-TR
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or ICD-10 speciﬁers. For case fatality, we will include
studies reporting on the percentage of persons diag-
nosed as having MDD who die as a result of the disease
within a given time period;35 and for excess mortality, we
will include studies reporting on relative risk (ie, deaths
in individuals with MDD compared with individuals
without MDD) or standardised mortality ratios (ie,
deaths in individuals with MDD compared with deaths
in the total population).33
In addition, studies examining the reliability and/or
validity of depression measurement tools will be selected
for inclusion if they meet all the aforementioned inclu-
sion criteria. Studies using symptom-based instruments
that mapped on the criteria proposed by DSM-V/
DSM-IV-TR and ICD-10 will also be included.
Randomised controlled trials, published in English, will
be included in cases where both the experimental and
control groups are selected from the same source popu-
lation or the larger population of which they are ideally
a representative sample.
Studies reporting on depressive symptoms, not speciﬁc
to MDD, will be excluded. For prevalence, lifetime esti-
mates will be excluded, as recall bias invalidates them as
credible measures of disease burden.33 Finally, studies
that report secondary outcomes and no primary out-
comes will be excluded. The primary and secondary out-
comes are listed in the ‘types of outcome measure’
section below.
Types of participants
We will include studies conducted on persons living in
South Africa, regardless of age, gender and study
setting. Studies conducted exclusively on recent immi-
grants or refugees will be excluded because they have a
very different risk proﬁle for major depression (usually
elevated) compared with the non-immigrants36–39 and
therefore will not be representative of the broader South
African population.40
Types of outcome measures
Primary outcomes
Prevalence: Point prevalence (ie, current or past month
prevalence), 6-month or 12-month period prevalence of
MDD.
Incidence: Cumulative incidence or incidence rate of a
major depressive episode (ie, number of new cases over
total person-years of follow-up susceptible).
Remission: Remission rate (ie, percentage of
‘untreated’ participants remitted at one or more
follow-up time-points in the study).
Duration: Average or median duration of a major
depressive episode.
Severity: Severity criteria (ie, mild, moderate or severe)
of a major depressive episode according to DSM-V/
DSM-IV-TR or ICD-10.
Case fatality: Case fatality rate (ie, percentage of
persons diagnosed as having MDD who die as a result of
the disease within a speciﬁed time period).
Excess mortality: Relative risk (ie, deaths in individuals
with MDD compared with individuals without MDD) or
standardised mortality ratios (ie, deaths in individuals
with MDD compared with deaths in the total
population).
Secondary outcome
Risk factors for MDD. Risk factors for this mood dis-
order cited in the literature are sociodemographic
factors (such as age, gender, occupation, educational
level, marital status, employment status, ethnicity, socio-
economic status), familial factors (such as family history
of MDD, family conﬂict), stressful life events (eg, death,
assault, marital discord, divorce), comorbidity (eg, sub-
stance use disorder, psychiatric disorders and medical ill-
nesses) and early trauma (eg, early childhood
maltreatment; early prolonged emotional, physical and
sexual abuse and early death of a parent).41 42
Search strategy
The search strategy aims to ﬁnd published articles
written in English, that described the prevalence, inci-
dence, remission, duration, severity of, case fatality or
excess mortality of MDD, that were conducted from
January 1997 up to December 2015. The electronic data-
bases that will be searched are CINAHL, JTSOR,
Popline, PubMed, Science Direct, Scopus, Web of
Science, PsycINFO, PsychARTICLES and PsychBooks
(table 1). The time period was chosen because we have
YLL estimates for this period which will be combined
with the YLD estimates obtained through disease model-
ling to calculate the DALY.
Experts in the ﬁeld will be consulted to inform about
possible non-journal literature and local data sources.
We will also check reference lists of included studies and
other relevant publications for additional studies.
Study selection
The titles and abstracts of the search output will be
screened independently by two review authors in order to
identify potentially eligible studies. Full-text articles of
Table 1 PubMed search strategy, modified as appropriate
for use in other databases
Search Query
#4 Search ((#3 NOT (animals[mh] NOT humans
[mh]))) AND (“1997/01/01″[Date—Publication] :
“2015/12/31″[Date—Publication])
#3 Search (#1 AND #2)
#2 Search (South Africa[mh] OR South Africa*[tiab]
OR RSA[tiab] OR Africa, Southern[mh:noexp]
OR Southern Africa[tiab])
#1 Search (Depression[Mesh] OR “Depressive
Disorder”[Mesh] OR “Depressive Disorder,
Major”[Mesh] OR “major depression”[tiab] OR
“major depressive disorder”[tiab] OR dysthymi*
[tiab])
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these studies will be obtained and two authors will inde-
pendently examine these for inclusion in the review using
prespeciﬁed criteria. Any disagreements will be resolved
by discussion and consensus involving the two authors, or
a third review author who will arbitrate, if needed.
Data extraction
A standardised data extraction form will be used for data
extraction. Two authors will independently perform data
extraction. Any disagreements arising during the data
extraction process will be resolved by discussion and
consensus involving the two authors or a third review
author will arbitrate, if needed. Information will be
extracted regarding study title, author(s), year of study
and publication; study design/data source; population
characteristics such as age and sex; study setting and
geographic location (such as rural, urban); details of
outcome measures; and details necessary to assess the
risk of bias. Authors of reports/articles will be contacted
for additional information on unclear or missing data.
Risk of bias assessment
Two authors will independently assess the risk of bias and
methodological quality for each study using a piloted
checklist43 adapted from the risk of bias tool for
population-based studies described by Hoy et al44 and the
Newcastle-Ottawa Scale for assessing the quality of non-
randomised studies.45 The dimensions covered in the
checklist include external validity (ie, representativeness,
non-response bias and loss to follow-up) and internal val-
idity (ie, case deﬁnition, measurement of cases and con-
sistency of measurement of cases, uncertainty of
estimation, appropriateness of time factor for outcome
measure, appropriateness of numerator and denomin-
ator in calculation of estimate and confounding).43 This
will be assessed qualitatively in terms of the anticipated
impact on bias. In addition, total scores of the risk of bias
will be taken into account which range from 1 to 20: a
score of 1–6 will be rated high risk, 7–13 moderate risk,
and 14–20 low risk.43 Differences between the two
authors will be resolved by discussion and consensus and
a third author will arbitrate, if needed.
Data synthesis
Separate meta-analyses will be performed for quantita-
tive data on prevalence, incidence, remission, duration,
severity, case fatality and excess mortality for MDD from
studies rated as low or moderate risk using STATA 13
(StataCorp, College Station, Texas, USA). We will
combine the study-speciﬁc estimates and obtain the
overall summary estimate and 95% CI across studies.
Clinical heterogeneity will be investigated by looking at
the types of participants in each study. The χ2 test will
be used to identify statistically signiﬁcant heterogeneity.
The latter will be considered to exist when χ2
p≤0.10.46 47 The I2 statistic will be used to evaluate the
degree of heterogeneity. If the study results are found to
be statistically homogeneous (ie, when χ2 p>0.10), we
will pool them using the ﬁxed-effect meta-analysis.
Otherwise, we will use random effects meta-analysis.
Potential publication bias will be assessed by visual
inspections of funnel plots.48 Where studies are found to
be clinically and statistically heterogeneous, we will
conduct a narrative synthesis including tables and
ﬁgures. We anticipate that the paucity of published
studies reporting on incidence, remission, duration,
severity, case fatality and excess mortality of MDD and
the heterogeneous nature of the reported results will
preclude meta-analysis. In this event, only a narrative
synthesis of results will be conducted.
For risk factors for MDD, in anticipation of the large
variability in their investigation and reporting across
studies, only a narrative synthesis of the evidence will be
conducted, including tables. For studies rated low or
moderate risk, we will report the measure of association
used for each of the risk factors investigated with their
corresponding 95% CI and indicate whether those mea-
sures were adjusted for confounders or not. Further, we
will document the number of risk factors reported to be
associated with MDD and tabulate the most commonly
reported risk factors for MDD.
Analysis of subgroups or subsets
Where sufﬁcient data are available, subgroup analyses
will be performed by population group where identiﬁed,
MDD assessment instrument, rural/urban settings, and
study designs.
Confidence in cumulative evidence
The grading of recommendations, assessment, develop-
ment and evaluation (GRADE) approach will be used to
assess the certainty of the body of evidence.49 50 This
method results in the assessment of the certainty of the
body of evidence as high, moderate, low or very low.
The evidence is considered of high certainty if further
research very unlikely to change our conﬁdence in the
effect estimate; and moderate certainty if further
research is likely to have an important impact on our
conﬁdence in the estimate of the effect and may change
the estimate. The low certainty evidence implies that
further research is likely to have an important impact on
our conﬁdence in the effect estimate and may change
the estimate, and very low certainty implies that we have
very little conﬁdence in the effect estimate and there is
uncertainty in the effect estimates.
ETHICS AND DISSEMINATION
The systematic review does not require ethics approval
because published studies with non-identiﬁable data will
be used. None of the data can be linked to an individ-
ual. This protocol complies with the ‘Preferred
Reporting Items for Systematic Review and Meta-Analysis
Protocols (PRISMA-P)’ guidelines51 and any amend-
ments that prove necessary will be tracked, documented
and reported transparently. In addition, the ﬁndings of
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the systematic review will be reported according to the
PRISMA statement,52 and will have important implica-
tions for epidemiological modelling and research. The
review will shed light on the evidence base for epidemio-
logical studies on MDD and the availability of nationally
representative local epidemiological data which are
needed for the disease modelling of MDD to estimate
YLDs; ultimately, these estimates will be combined with
YLLs to calculate the DALYs which will inform policy-
makers and funding bodies regarding decisions on
where to focus policy, service and research planning and
implementation. Also, the ﬁndings may inﬂuence future
studies to improve study methodology. For example, the
use of similar assessment instruments to diagnose MDD
will allow for effective comparisons across studies.
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